List of Genvoya drug patents

Genvoya is owned by Gilead Sciences Inc.

Genvoya contains Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate.

Genvoya has a total of 21 drug patents out of which 1 drug patent has expired.

Expired drug patents of Genvoya are:

  • US7803788

Genvoya was authorised for market use on 05 November, 2015.

Genvoya is available in tablet;oral dosage forms.

Genvoya can be used as treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase, treatment of hiv infection.

The generics of Genvoya are possible to be released after 06 April, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(3 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US8148374 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(11 months ago)

US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US7176220

(Pediatric)

GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(4 years from now)

US7635704

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US8981103

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US9891239 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

US8148374

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(7 years from now)

US9891239

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(7 years from now)

US8633219 GILEAD SCIENCES INC Combination therapy
Apr, 2030

(7 years from now)

US8633219

(Pediatric)

GILEAD SCIENCES INC Combination therapy
Oct, 2030

(7 years from now)

US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(10 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in